Library Publications

Wedemeyer R-S, Blume H

NSAIDs: drug group woth relevant need for galenic improvement

Pharmakon 5 (1): 21-31, 2017

Schug BS, Donath F, Blume HH

Bioavailability and pharmacodynamics of two 10-mg estradiol valerate depot formulations following i.m. single dose administration in healthy postmenopausal volunteers

Int J Clin Pharmacol Ther. 50 (2): 100-117, 2012

Donath F, Braeter M, Feustel C

The influence of propiverine hydrochloride on cardiac repolarization in healthy women and cardiac male patients

Int J Clin Pharmacol Ther. 49 (6): 353-365, 2011

Blume HH, Wedemeyer RS

Austausch von starken Opioiden? – Die therapiäquivalente Arzneimittelqualität muss gewährleistet sein

Dtsch Apoth Ztg. 150 (47): 84-89, 2010

Sabatowski R, Grond S, Blume HH

Anforderungen an einer optimierte Opioidtherapie chronischer Schmerzen. Gleichmäßige Plasmaspiegel versus chronoadjustierte Analgesie

MMW Fortschr Med. 152: 12-15, 2010

Stauss-Grabo M, Warnke A, Atiye S, Wedemeyer RS, Blume HH

Investigation of the tolerability and safety of film-coated tablets containing ivy extracts (Prospan ® Cough Tablets) in the treatment of colds accompanied by coughing

58th International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Products Research, Berlin, 29th August-2nd September, 2010

Blume HH, Schug BS

Bioavailability/bioequivalence requirements of immediate release products: resolutions and issues

In Bioavailability, Bioequivalence and Pharmacokinetic Studies, K. Midha & T. Nagau, eds., Business Centre for Academic Societies Japan, (2010) pp. 101-106

Weitschies W, Blume HH, Mönnikes H

Magnetic Marker Monitoring: High resolution real-time tracking of oral solid dosage forms in the gastroinestinal tract

Eur J Pharm Biopharm. 74 (1): 93-101, 2010

Warnke A, Schug BS, Vanderbist F, Blume HH

Significance of the biopharmaceutical properties of tramadol sustained-release formulations for chrono-pharmacologically optimized treatment of pain from various sources

Int J Clin Pharmacol Ther. 47 (6): 405-412, 2009

Schug BS, Blume HH

Schneller am Ziel mit Magnetic Marker Monitoring

DZKF. 12 (7-8): 51-56, 2008

Warnke A, Schug BS, Vanderbist F, Blume HH

Importance of the formulation for a chronopharmacologically optimised way of pain therapy. Results of a comparative bioavailability study of tramadol extended-release capsules after single-dose evening versus morning administration

MMW Fortschr Med. 150 (1): 36-42, 2008

Richert H, Kosch O, Görnert P

Magnetic Monitoring as a Diagnostic Method for Investigating Motility in the Human Digestive System

in ´Magnetism in Medicine´, a Handbook, edited by Andrä W and Nowak H, Second Edition, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, 2007

Blume HH, Schug BS, Tautz J, Erb KA

Neue Richtlinien für die Beurteilung der Bioverfügbarkeit/ Bioäquivalenz

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 2005 48: 548-555, 2005

Lehmann G, Folchert F, Schug BS, Anschütz M

Charakterisierung der Magenentleerung einer proteinhydrolysathaltigen, kohlenhydratreichen Trinknahrung im Vergleich zu einer kohlenhydratreichen Referenznahrung

Hauptstadtkongress für Anästhesiologie und Intensivmedizin, Berlin 09.06.-11.06.2005

Warnke A, Blume HH

Wie die Arzneiform zum Therapieerfolg beiträgt – Arzneizubereitungen mit Calciumkanal-Blockern

Pharm Unserer Zeit. 34 (5): 400-410, 2005

Wolf D, Folchert F, Blume HH

Gastric emptying and gastric residual volume after intake of a sip feed containing carbohydrates and protein hydrolysate

27th Congress of the European Society of Clinical Nutrition and Metabolism (ESPEN), Brussels 27.08. - 30.08.2005

Chen X, Zhong D, Xu H, Schug BS, Blume HH

Sensitive and specific liquid chromatographic-tandem mass spectrometric assay for dihydroergotamine and its major metabolite in human plasma

J Chromatogr B Analyt Technol Biomed Life Sci. 768 (2): 267-275, 2002

Chen X, Zhong D, Xu H, Schug BS, Blume HH

Simultaneous determination of flupirtine and its major active metabolite in human plasma by liquid chromatography-tandem mass spectrometry

J Chromatogr B Biomed Sci Appl. 755 (1-2): 195-202, 2001

Blume HH, Schug BS

Biopharmaceutical characterisation of herbal medicinal products: are in vivo studies necessary?

Eur J Drug Metab Pharmacokinet. 25 (1): 41-48, 2000

Blume HH, Schug BS

Qualität von Eisenpräparaten

Dtsch Apoth Ztg. 139 (7): 47- 50, 1999

Blume HH, Schug BS

The biopharmaceutics classification system (BCS): class III drugs – better candidates for BA/BE waiver?

Eur J Pharm Sci. 9 (2): 117-121, 1999

Schug BS, Blume HH

Qualität von Eisenpräparaten – Sind Bioverfügbarkeitsprüfungen erforderlich?

Dtsch Apoth Ztg. 139 (7): 719-722, 1999

Mazur D, Schug BS, Elze M, Blume HH

Planung, Durchführung und Auswertung klinischer Studien

In Lehrbuch der klinischen Pharmazie, U. Jaehde et al., eds., Wissenschaftliche Verlagsgesellschaft Stuttgart, (1998) pp. 115-137

Schug BS, Hermann R, Blume HH, Elze M

Gender effect on the pharmacokinetics of thioctic acid: an evaluation of several bioavailability studies

Naunyn Schmiedebergers Arch Pharmacol, 357 (suppl.)/ (1998)

Schug BS

Das Biopharmazeutische Klassifizierungssystem BCS – Neuer Ansatz bei der Beurteilung von Arzneimitteln

Dtsch Apoth Ztg. 138 (23): 45-51, 1998

Ali S, Blume HH, Schug BS

Sulfonylureas: Physico-chemical properties, analytical methods of determination and bioavailability

In Handbook of Experimental Pharmacology 119, Oral Antidiabetics, J. Kuhlmann & W. Puls, eds., Springer Verlag Berlin, Heidelberg, New York, (1996)

Blume HH, Schug BS

Bioavailability/ Bioeqivalence requirements of immediate release products: resolutions and issues

In Bioavailability, Bioequivalence and Pharmacokinetic Studies, K. Midha & T. Nagai, eds., Business Centre for Academic Societies Japan, (1996) pp. 85-90

Blume HH, Schug BS, Potthast H

Influence of food on the bioavailability of controlled/modified release products, in: Kuhlmann J, Weihrauch TR (eds.).

Eur J Clin Pharmacol. 12: 25-32, 1996

Lipka E, Crison J, Schug BS, Blume HH, Amidon G

Drug interactions in the gastrointestinal tract and their impact on drug absorption and systemic availability: a mechanistic review

In Handbook of experimental pharmacology, Mechanisms of drug interactions, P. D Arcy, J. McElnay, & P. Welling, eds., Springer Verlag Berlin, Heidelberg, New York, (1996) pp. 13-21

Schug BS, Elze M, Blume HH

Bioequivalence of highly variable drugs and drug products: steady state studies

In Bioavailability, Bioequivalence and Pharmacokinetic Studies, K. Midha & T. Nagau, eds., Business Centre for Academic Societies Japan, (1996) pp. 101-106

Schug BS, Blume HH

Possibilities and limitations on the interpretation of pharmacokinetic interaction studies (drug-drug, drug-food)

Pharm Unserer Zeit. 25 (4): 195-196, 1996

Blume HH, Elze M, Potthast H, Schug BS

Practical strategies and design advantages in highly variable drug studies: multiple dose and replicate administration design

In Bio-international 2, Bioavailability, Bioequivalence and Pharmacokinetic Studies, H. Blume & K. Midha, eds., medpharm Scientific Publishers Stuttgart, (1995) pp. 117-122

Potthast H, Schug BS, Blume HH

Vergleich von Erythromycinestolat und Erythromycinethylsuccinat

Sozialpädiatrie und Kinderärztliche Praxis, 17/ (1995) 284-286

Schug BS, Kalbhen DA

Influence of chloroquine and other substances on the collagenolytic activity in human osteoarthritic cartilage in vitro

Arzneimittelforschung. 45 (3): 285-289, 1995

Schug BS, Blume HH

Bio International 1994: Wichtige Ergebnisse

Pharm Ztg. 139: 2800-2806, 1994

Schug BS, Kalbhen DA

Human recombinant interleukin-1 alpha and beta and articular tissue integrity. An in vivo study on hens and rats

Arzneimittelforschung. 42 (6): 880-881, 1992

Schug BS, Kalbhen DA

Beeinflussung der Aktivität von Kollagenasen durch verschiedene antirheumatische Wirkstoffe

Pharm Unserer Zeit. 3: 118-119, 1991

All fine on page library publications